Table 1_Circulating immune cell profiling in advanced cervical and endometrial cancer pati

Regina Esi Mensimah Baiden-Amissah published longitudinal immune profiling data from 43 advanced cervical and endometrial cancer patients in the PRIMMO clinical trial. The dataset includes measurements of immune cell subsets and systemic mediators from blood samples collected at baseline, week 7, and week 26. It was last updated on 2026-05-21.

Use Cases

• Identify baseline immune biomarkers associated with survival outcomes based on CTLA-4+PD-1+CD4+ T cells and CD161+CD56+CD16+ NK cells.
• Model longitudinal immune changes distinguishing responders from non-responders based on profiles of pDCs, T cell activation markers, and immunoregulatory populations.
• Compare tumor-type-specific immune dynamics based on suggested NK-related changes in cervical cancer and T cell-related changes in endometrial cancer.
• Investigate associations between systemic immune mediators and treatment response based on kynurenine/tryptophan ratio and sPD-1 levels.

Strengths

• Data is longitudinal, with samples collected at three time points: baseline, week 7, and week 26.
• Includes profiles from 43 patients (19 cervical cancer, 24 endometrial cancer) from a defined clinical trial (NCT03192059).
• Immune profiling was performed using specific, high-resolution methods: multicolor flow cytometry and ELISA.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 2.8 MB, which may limit the scope of analysis.

Provenance

Source

figshare

Collection Method

Blood-based immune profiles were assessed by multicolor flow cytometry and ELISA from patients in the PRIMMO clinical trial.

Freshness

Last updated 2026-05-21 05:35:12; freshness should be verified.